Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Inozyme Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	139.75	235.49	425.25	516.85	840.32	898.64
Short-Term Investments	886.04	1,117	419.06	667.67	589.89	372.26
Trading Asset Securities	-	-	-	-	21.89	-
Cash & Short-Term Investments	1,026	1,353	844.31	1,185	1,452	1,271
Cash Growth	68.43%	60.23%	-28.72%	-18.43%	14.26%	103.34%
Accounts Receivable	1.3	20.63	12	14	9.69	13.84
Other Receivables	13.87	19.16	18.13	17.98	17.01	16.38
Receivables	15.17	39.79	30.14	31.98	26.7	30.22
Inventory	96.63	97.78	103.91	108.68	82.39	31.78
Prepaid Expenses	61.69	46.64	65.66	60.88	59.17	13.65
Other Current Assets	0.39	0.02	0.02	-	0.13	0.02
Total Current Assets	1,200	1,537	1,044	1,386	1,620	1,347
Property, Plant & Equipment	19.99	19.68	27.53	7.66	13	19.5
Long-Term Investments	532.17	575.42	583.79	464.72	671.32	246.72
Goodwill	-	-	-	-	-	78.49
Other Intangible Assets	0.43	0.49	0.6	26.93	43.57	92.72
Other Long-Term Assets	0.32	0.32	0.32	0.32	0.32	0.32
Total Assets	1,753	2,133	1,656	1,886	2,349	1,784
Accounts Payable	0.35	1.42	1.49	12.25	14.5	0.03
Accrued Expenses	-	36.7	54.41	33.62	43.26	28.68
Current Portion of Leases	6.85	4.2	4.49	4.33	5.4	5.83
Current Unearned Revenue	2.8	3.04	3.04	6.88	4.68	0.32
Other Current Liabilities	109.99	155.83	156.14	158.28	156.18	155.65
Total Current Liabilities	119.99	201.18	219.58	215.36	224.03	190.5
Long-Term Leases	3.48	4.28	8.12	0.36	6.08	11.13
Total Liabilities	123.47	205.46	227.69	215.72	230.11	201.63
Common Stock	1,688	1,689	1,650	1,631	1,632	1,474
Additional Paid-In Capital	300.28	2,223	1,363	1,268	1,271	963.36
Retained Earnings	-252.1	-1,919	-1,494	-1,256	-761.44	-857.38
Comprehensive Income & Other	-62.99	-81.59	-117.45	-13.53	-22.98	2.96
Total Common Equity	1,617	1,912	1,401	1,630	2,119	1,583
Minority Interest	12.56	15.84	27.89	40.18	-	-
Shareholders' Equity	1,629	1,928	1,429	1,670	2,119	1,583
Total Liabilities & Equity	1,753	2,133	1,656	1,886	2,349	1,784
Total Debt	10.33	8.48	12.61	4.69	11.49	16.95
Net Cash (Debt)	1,015	1,344	831.7	1,180	1,441	1,254
Net Cash Growth	69.67%	61.64%	-29.51%	-18.10%	14.89%	104.46%
Net Cash Per Share	6.12	8.22	5.12	7.26	9.55	10.38
Filing Date Shares Outstanding	166.2	168.9	164.97	163.1	163.15	147.37
Total Common Shares Outstanding	166.2	168.9	164.97	163.1	163.15	147.37
Working Capital	1,080	1,336	824.46	1,171	1,396	1,156
Book Value Per Share	9.73	11.32	8.49	9.99	12.99	10.74
Tangible Book Value	1,616	1,911	1,400	1,603	2,075	1,411
Tangible Book Value Per Share	9.72	11.32	8.49	9.83	12.72	9.58
Machinery	-	41.95	41.5	31.82	29.53	29.53
Leasehold Improvements	-	3.21	3.21	-	-	0.24

Source: S&P Global Market Intelligence. Standard template. Financial Sources.